Kondoh 2016.

Methods	Parallel randomised trial investigating mosaprid in patients receiving remifentanil for labour analgesia. The study is not yet recruiting. The author's origin is Japan. Trial identifier: JPRN‐UMIN000021322
Participants	Inclusion criteria: pregnant women with the wish for labour pain relief, age > 20 years. Exclusion criteria: patients who can not consent, < 22 weeks of pregnancy, history of a high degree of hypersensitivity reactions to other drugs, impaired consciousness.
Interventions	Mosaprid administration versus mosaprid 5 mg every 4 h during the first labour phase versus no treatment
Outcomes	The primary outcome is pain control and the presence or absence of maternal respiratory depression. Secondary outcomes are drug administration time, drug bolus administration number of times, the presence or absence of labour induction, patient satisfaction, final delivery mode, Apgar score, the presence or absence of umbilical cord arterial blood pH, birthweight, neonatal complications.
Notes	This study is expected to be excluded (wrong intervention).